Last reviewed · How we verify
Placebo of Rituximab
Placebo of Rituximab is a Small molecule drug developed by University Hospital, Tours. It is currently in Phase 3 development for Control arm in phase 3 clinical trials (specific indication depends on the rituximab trial design).
This is a placebo control with no active pharmacological mechanism.
This is a placebo control with no active pharmacological mechanism. Used for Control arm in phase 3 clinical trials (specific indication depends on the rituximab trial design).
At a glance
| Generic name | Placebo of Rituximab |
|---|---|
| Sponsor | University Hospital, Tours |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo of rituximab, this formulation contains no active drug and serves as a control arm in clinical trials to assess the efficacy and safety of the actual rituximab therapy. Any observed effects would be attributable to placebo response rather than direct pharmacological action.
Approved indications
- Control arm in phase 3 clinical trials (specific indication depends on the rituximab trial design)
Common side effects
- Adverse events expected to reflect background disease progression and placebo response
Key clinical trials
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- Iptacopan in Patients With ANCA Associated Vasculitis (PHASE2)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis (PHASE2)
- Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma (PHASE3)
- Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (PHASE3)
- Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) (PHASE2)
- A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of Rituximab CI brief — competitive landscape report
- Placebo of Rituximab updates RSS · CI watch RSS
- University Hospital, Tours portfolio CI